Consensus Incyte Corporation

Stocks

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq 00:00:00 10/09/2026 +04			5-day change	1st Jan Change
126.01 ^USD	+1.29%		-2.19%	+27.58%

09-09	Incyte Corporation Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 11:00 AM
09-01	Incyte Corporation Enters Agreement with U.S. Centers for Medicare & Medicaid Services	CI

Evolution of the Average Target: Incyte Corporation

Evolution of the Target Price: Incyte Corporation

Changes in Analyst Recommendations: Incyte Corporation

58c236e.pukSEcc85dO_y86QjHZirKYOTOcI1fcYqfITl5HlNSM.i6cjV6xTppLtkZvp7R8FzcpbCrFOt5hyxYte9KKHXULAj2Rbqg234O6CqQ~3fd73209943f78e01a88279d6c3d2f92

Analysts' recommendations: Incyte Corporation

08-20	Canaccord Genuity Initiates Incyte at Buy With $152 Price Target	MT
08-17	Piper Sandler Adjusts Price Target on Incyte to $130 From $110, Maintains Overweight Rating	MT
08-13	Bernstein Adjusts Price Target on Incyte to $104 From $99, Keeps Market Perform Rating	MT
08-03	Mizuho Adjusts Price Target on Incyte to $137 From $121	MT
08-03	Leerink Partners Adjusts Price Target on Incyte to $155 From $131, Maintains Outperform Rating	MT
07-31	Argus Adjusts Price Target on Incyte to $140 From $115, Maintains Buy Rating	MT
07-30	JPMorgan Adjusts Price Target on Incyte to $120 From $110, Maintains Neutral Rating	MT
07-29	Incyte's Solid Q2 Seen Funding Strategy Beyond Jakafi Patent Expiration, RBC Says	MT
07-29	TD Cowen Adjusts Incyte Price Target to $138 From $124, Maintains Buy Rating	MT
07-29	Barclays Adjusts Incyte Price Target to $139 From $134, Maintains Overweight Rating	MT
07-29	Morgan Stanley Adjusts Incyte PT to $119 From $104, Maintains Equal Weight Rating	MT
07-29	BMO Capital Adjusts Incyte Price Target to $130 From $112, Maintains Market Perform Rating	MT
07-29	Jefferies & Co Adjusts Incyte Price Target to $115 From $105, Maintains Hold Rating	MT
07-29	Guggenheim Adjusts Incyte Price Target to $150 From $136, Maintains Buy Rating	MT
07-29	HC Wainwright Raises Incyte Price Target to $150 From $140, Maintains Buy Rating	MT
07-29	Goldman Sachs Adjusts Incyte Price Target to $118 From $110, Maintains Neutral Rating	MT
07-29	RBC Raises Price Target on Incyte to $109 From $99, Keeps Sector Perform Rating	MT
07-28	Oppenheimer Raises Incyte Price Target to $120 From $107	MT
07-28	Stifel Raises Incyte Price Target to $145 From $123, Buy Rating Kept	MT
07-28	Wells Fargo Adjusts Price Target on Incyte to $116 From $101	MT
07-23	JPMorgan Adjusts Price Target on Incyte to $110 From $105, Maintains Neutral Rating	MT
07-22	Morgan Stanley Adjusts Price Target on Incyte to $104 From $103, Maintains Equalweight Rating	MT
07-20	Goldman Sachs Adjusts Price Target on Incyte to $110 From $100, Maintains Neutral Rating	MT
07-15	BofA Securities Raises Incyte Price Target to $136 From $124	MT
07-14	Barclays Adjusts Incyte Price Target to $134 From $117, Maintains Overweight Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	INCYTE CORPORATION					+1.37%
	REGENERON PHARMACEUTICALS, INC.					+5.16%
	CSL LIMITED					-0.18%
	MODERNA, INC.					-14.09%
	SAMSUNG BIOLOGICS CO.,LTD.					+35.5%
	UCB					+39.3%
	BIOGEN INC.					+12.56%
	INNOVENT BIOLOGICS, INC.					+30.89%
	SWEDISH ORPHAN BIOVITRUM AB					+13.02%
	BRIDGEBIO PHARMA, INC.					+43.4%
	Average					+16.69%
	Weighted average by Cap.					+12.93%